by Jason Heaviland | Dec 5, 2025 | Uncategorized
The pharmaceutical and biotechnology industries face a persistent challenge in metabolomics research: translating exploratory discoveries into validated, quantifiable biomarkers suitable for clinical development. Traditional approaches force researchers to choose...
by Jason Heaviland | Dec 3, 2025
From Metabolism to Mechanism, Profile PRMT5 Activity in Cancer Profile PRMT5 activity with precise SDMA/ADMA quantification and full methionine cycle coverage. Support inhibitor development, patient stratification, and tumor profiling.
by Jason Heaviland | Dec 2, 2025
Beyond Plaques and Tangles: How Untargeted Metabolomics Detects Distinct Signatures in Alzheimer’s Disease Untargeted metabolomics captures systemic metabolic changes in neurodegenerative diseases, such as Alzheimer’s, identifying altered pathways and...
by Jason Heaviland | Nov 25, 2025 | Uncategorized
Dietary intervention studies have historically relied on a limited panel of predefined endpoints: glucose and lipid profiles, inflammatory markers, anthropometric measurements, and questionnaire-based assessments. While these traditional biomarkers provide valuable...
by Janine Rodriguez | Nov 25, 2025
ChatGJP: Insights from Gary Patti on Mass Spec and Multi-Omics In this episode of the ChatGJP series, Panome Bio CSO Gary Patti shares candid insights into his research at Washington University in St. Louis, his work with Panome Bio, and the evolving landscape of mass...
